Evidence map›Paper›PMID 41909595›Full record

ArticleInternational journal of general medicine2026

Assessing the Lower Incidence of Invasive Pneumococcal Diseases in Japan During the COVOD-19 Pandemic.

Masafumi Seki, Daishi Shimada

Abstract read
In one paragraph

Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Masafumi SekiDivision of Infectious Diseases and Infection Control, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan.ORCID 0000-0001-5414-8148
Daishi ShimadaDivision of Respiratory Medicine, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Miyagi, Japan.ORCID 0000-0001-8886-6930

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During the COVID-19 pandemic from 2020 to 2023 in Japan, in our hospital there were seven cases of invasive pneumococcal diseases (IPDs) in this COVID-19 pandemic period although 14 IPD cases were treated in 2019, 2024, and 2025, such as pre-/post- COVID-19 pandemic period. Of these total 21 IPD patients, five (23.8%) died, and they were all treated during pre-/post-pandemic period. Only 2 of the 21 patients (9.5%) children had been vaccinated. Furthermore, compared with survivors, those who died were younger (54.0 vs 69.4 years old, p = 0.0011), had lower white blood cell counts (3672.1 vs 12117.3/µL, p = 0.0011), and had higher C-reactive protein levels (34.5 vs 22.1 mg/dL, p = 0.0010). Two or more bacteria were isolated, and multiple and/or broad antimicrobial agents were used in fatal cases. These data suggested that IPD cases decreased and might have been less pathogenic during the COVID-19 pandemic period than in the pre-/post-COVID-19 pandemic period. In addition, those who died were younger, more septic due to multiple bacterial infections, and received more and broader antimicrobial agents than survivors. No adult patients received pneumococcal vaccination, which suggests that low vaccination rates lead to the high mortality of adult IPD patients.

Indexed as

COVID-19invasive pneumococcal diseasesmeropenemStreptococcus pneumoniaevaccine

Identifiers

PMID41909595
PMCPMC13019354

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.